Trials / Completed
CompletedNCT01043458
Pharmacokinetic Study of ABT-126 in Stable Subjects With Schizophrenia
A Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of ABT-126 in Stable Subjects With Schizophrenia
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
A study to investigate the process by which ABT-126 is absorbed, distributed, metabolized and eliminated by the body of stable schizophrenic volunteers receiving treatment with an atypical antipsychotic.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABT-126 | ABT-126 Low Dose \& ABT-126 High Dose |
| DRUG | Placebo for ABT-126 | Matching Placebo for Arms 1 \& 2 |
Timeline
- Start date
- 2009-11-01
- Primary completion
- 2010-01-01
- First posted
- 2010-01-06
- Last updated
- 2010-11-02
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01043458. Inclusion in this directory is not an endorsement.